J. Armitage

Publications849
h-index101
Citations64,697
Highly Influential Citations2,192
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Vose
  • 836 Publications • 51,456 Citations
  • D. Weisenburger
  • 603 Publications • 65,750 Citations
  • E. Jaffe
  • 997 Publications • 109,838 Citations
  • R. Gascoyne
  • 942 Publications • 87,107 Citations
  • Publications
  • Influence
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
TLDR
It is shown that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour. Expand
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
TLDR
In summary, immunostains can be used to determine the GCB and non-GCB subtypes of DLBCL and predict survival similar to the cDNA microarray. Expand
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
TLDR
DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma and this gene-based predictor and the international prognostic index were independent prognostic indicators. Expand
Stromal gene signatures in large-B-cell lymphomas.
TLDR
Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP. Expand
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
TLDR
Reduction in febrile neutropenia (FN) is an important clinical outcome that justifies the use of CSFs, regardless of impact on other factors, when the risk of FN is approximately 20% and no other equally effective regimen that does not require CSFs is available. Expand
New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.
TLDR
The findings for the 13 most common lymphoma types that will be encountered in clinical practice are presented and it is important that clinicians be knowledgeable with regard to their clinical characteristics. Expand
A predictive model for aggressive non-Hodgkin's lymphoma.
TLDR
The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients. Expand
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
TLDR
Gene expression profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkinymphoma cells. Expand
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
TLDR
The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis. Expand
Molecular diagnosis of Burkitt's lymphoma.
TLDR
Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma and the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens. Expand
...
1
2
3
4
5
...